Drug search by name

Advicor and Renal dysfunction

Result of checking the interaction of drug Advicor and disease Renal dysfunction for safety when used together.

Check result:

Advicor <> Renal dysfunction

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

In patients with severe renal impairment (CrCl < 30 mL/min.), the plasma concentrations of total HMG-CoA reductase inhibitors after a single dose of lovastatin may be approximately two-fold higher than those in healthy patients, presumably due to the accumulation of active metabolites. Increased HMG-CoA reductase inhibitory activity may be associated with a greater risk of adverse effects, including hepatic and musculoskeletal toxicities. Therefore, lovastatin dosage increases above 20 mg/day should be considered and implemented cautiously in patients with severe renal impairment. Close clinical monitoring is recommended during therapy.

References:

Lennernas H, Fager G "Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences." Clin Pharmacokinet 32 (1997): 403-25
"Product Information. Mevacor (lovastatin)." Merck & Co, Inc, West Point, PA.
Pan HY, DeValut AR, Wang-Iverson D, et al "Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin." J Clin Pharmacol 30 (1990): 1128-35
Duggan DE, Chen IW, Bayne WF, Halpin RA, Duncan CA, Schwartz MS, Stubbs RJ, Vickers S "The physiological disposition of lovastatin." Drug Metab Dispos 17 (1989): 166-73

Advicor

Generic Name: lovastatin / niacin

Brand Name: Advicor

Synonyms: n.a.

What is Advicor?